{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:43:45Z","timestamp":1793774625880,"version":"4.6.1"},"reference-count":230,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.prp.2024.155518","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T01:39:02Z","timestamp":1723253942000},"page":"155518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Potential alternatives to \u03b1\u03b2-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review"],"prefix":"10.1016","volume":"262","author":[{"given":"Chaozhi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155518_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122683","article-title":"The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods","volume":"348","author":"Metanat","year":"2024","journal-title":"Life Sci."},{"issue":"19","key":"10.1016\/j.prp.2024.155518_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912366","article-title":"Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.prp.2024.155518_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib4","first-page":"79","article-title":"Barriers to patient access of CAR T cell therapies in Austria","volume":"16","author":"Hopfinger","year":"2023","journal-title":"Memo. - Mag. Eur. Med. Oncol."},{"key":"10.1016\/j.prp.2024.155518_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275329","article-title":"Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors","volume":"14","author":"Binder","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.prp.2024.155518_bib6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.prp.2024.155518_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2024.155518_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T Cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780145","article-title":"Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: results of recent clinical trials","volume":"12","author":"Smirnov","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front. Oncol."},{"issue":"417","key":"10.1016\/j.prp.2024.155518_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1209","article-title":"TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance","volume":"9","author":"Yang","year":"2017","journal-title":"Sci. Transl. Med"},{"issue":"9","key":"10.1016\/j.prp.2024.155518_bib12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol. Immunol."},{"issue":"12","key":"10.1016\/j.prp.2024.155518_bib13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17544","article-title":"Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells","volume":"195","author":"Sanber","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/stcltm\/szab025","article-title":"Shipping and logistics considerations for regenerative medicine therapies","volume":"11","author":"Criswell","year":"2022","journal-title":"Stem Cells Transl. Med"},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315592121","article-title":"\u03b3\u03b4 T cell antigen receptor polyspecificity enables T cell responses to a broad range of immune challenges","volume":"121","author":"Guo","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development?","volume":"16","author":"Zhao","year":"2018","journal-title":"J. Transl. Med."},{"issue":"24","key":"10.1016\/j.prp.2024.155518_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246212","article-title":"The diverse roles of \u03b3\u03b4 T cells in cancer: from rapid immunity to aggressive lymphoma","volume":"13","author":"Sch\u00f6nefeldt","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"\u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.4049\/jimmunol.1502202","article-title":"Molecular Analysis of Lipid-Reactive V\u03b41 \u03b3\u03b4 T Cells Identified by CD1c Tetramers","volume":"196","author":"Roy","year":"2016","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.prp.2024.155518_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239286","article-title":"Skin Resident \u03b3\u03b4 T Cell Function and Regulation in Wound Repair","volume":"21","author":"Munoz","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155518_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2018.02.007","article-title":"Butyrophilin3A proteins and V\u03b39V\u03b42 T cell activation","volume":"84","author":"Gu","year":"2018","journal-title":"Semin Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib25","article-title":"\u03b3\u03b4 T cells and their roles in immunotherapy: a narrative review","volume":"7","author":"Chen","year":"2021","journal-title":"Ann. Blood"},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib26","doi-asserted-by":"crossref","first-page":"1554175","DOI":"10.1080\/2162402X.2018.1554175","article-title":"Boosting \u03b3\u03b4 T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma","volume":"8","author":"Rossi","year":"2019","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin. Transl. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s12276-021-00576-0","article-title":"Function of \u03b3\u03b4 T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"M. Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcyt.2017.12.014","article-title":"Large-scale expansion of V\u03b39V\u03b42 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.","volume":"20","author":"Xiao","year":"2018","journal-title":"Cytotherapy"},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/imt-2018-0211","article-title":"Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo expansion of T lymphocytes","volume":"11","author":"Zha","year":"2019","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.37349\/ei.2022.00042","article-title":"Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors","volume":"2","author":"Ferry","year":"2022","journal-title":"Explor. Immunol."},{"issue":"598","key":"10.1016\/j.prp.2024.155518_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aax1872","article-title":"Engineering \u03b3\u03b4T cells limits tonic signaling associated with chimeric antigen receptors","volume":"12","author":"Fisher","year":"2019","journal-title":"Sci. Signal"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","article-title":"T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication","volume":"29","author":"Ng","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2024.155518_bib35","unstructured":"Bio A. Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001: Adicet Bio; 2022 [Available from: \u3008https:\/\/investor.adicetbio.com\/news-releases\/news-release-details\/adicet-bio-receives-fda-fast-track-designation-lead-candidate\/\u3009."},{"issue":"Supplement 1","key":"10.1016\/j.prp.2024.155518_bib36","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2022-157400","article-title":"A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (\u03b3\u03b4) T Cells in Adults with B-Cell Malignancies","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155518_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118681","article-title":"CAR-iNKT cells targeting clonal TCRV\u03b2 chains as a precise strategy to treat T cell lymphoma","volume":"14","author":"Rowan","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","article-title":"CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy","volume":"23","author":"Hadiloo","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.prp.2024.155518_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1176724","article-title":"Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes","volume":"14","author":"Look","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3389\/fimmu.2018.00384","article-title":"Novel approaches to exploiting invariant NKT cells in cancer immunotherapy","volume":"9","author":"Wolf","year":"2018","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4110\/in.2017.17.6.365","article-title":"Lineage differentiation program of invariant natural killer T cells","volume":"17","author":"Kwon","year":"2017","journal-title":"Immune Netw."},{"key":"10.1016\/j.prp.2024.155518_bib42","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3389\/fimmu.2017.01950","article-title":"Unraveling natural killer t-cells development","volume":"8","author":"Bennstein","year":"2017","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-023-00482-9","article-title":"New cell sources for CAR-based immunotherapy","volume":"11","author":"Mazinani","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2024.155518_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101342","article-title":"iNKT: a new avenue for CAR-based cancer immunotherapy","volume":"17","author":"Liu","year":"2022","journal-title":"Transl. Oncol."},{"issue":"7_Supplement","key":"10.1016\/j.prp.2024.155518_bib45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1538-7445.AM2023-913","article-title":"Abstract 913: Engineering allogeneic off-the-shelf CD19-directed CAR-iNKT cells without additional genetic manipulations for the treatment of hematological malignancies","volume":"83","author":"Ponnusamy","year":"2023","journal-title":"Cancer Res."},{"issue":"Supplement 1","key":"10.1016\/j.prp.2024.155518_bib46","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2023-186442","article-title":"Bispecific CAR-iNKT immunotherapy for high risk MLL-rearranged acute lymphoblastic leukemia","volume":"142","author":"Ren","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.prp.2024.155518_bib47","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2023010032","article-title":"Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc","volume":"7","author":"O\u2019Neal","year":"2023","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib49","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"issue":"2, Supplement","key":"10.1016\/j.prp.2024.155518_bib50","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","article-title":"Off-the-Shelf CD19-Specific CAR-NKT Cells in Patients with Relapsed or Refractory B-Cell Malignancies","volume":"30","author":"Ramos","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.prp.2024.155518_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584521","article-title":"MAIT Cells in Barrier Tissues: Lessons from Immediate Neighbors","volume":"11","author":"Amini","year":"2020","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib52","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2020.09.009","article-title":"MAIT Cell Development and Functions: the Microbial Connection","volume":"53","author":"Legoux","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib53","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","article-title":"Mucosal-associated invariant T cells for cancer immunotherapy","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib54","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.tim.2020.11.008","article-title":"Emerging Role for MAIT Cells in Control of Antimicrobial Resistance","volume":"29","author":"Leeansyah","year":"2021","journal-title":"Trends Microbiol"},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib55","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cancers13071502","article-title":"MAIT cells: partners or enemies in cancer immunotherapy","volume":"13","author":"Cogswell","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/imcb.12021","article-title":"Human blood MAIT cell subsets defined using MR1 tetramers","volume":"96","author":"Gherardin","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.prp.2024.155518_bib57","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3389\/fimmu.2020.01014","article-title":"MAIT cell activation and functions","volume":"11","author":"Hinks","year":"2020","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112749","article-title":"Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.prp.2024.155518_bib59","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","article-title":"Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy","volume":"209","author":"Dogan","year":"2022","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib60","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ymthe.2022.12.015","article-title":"Retraction Notice to: selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus","volume":"31","author":"Gao","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2024.155518_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.613204","article-title":"CD8+CD161+ T-cells: cytotoxic memory cells with high therapeutic potential","volume":"11","author":"Konduri","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2020.00751","article-title":"MR1-Restricted T Cells Are Unprecedented Cancer Fighters","volume":"11","author":"Vacchini","year":"2020","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.prp.2024.155518_bib63","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00262-015-1764-7","article-title":"Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients","volume":"64","author":"Zabijak","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"10s","key":"10.1016\/j.prp.2024.155518_bib64","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.bulcan.2021.07.003","article-title":"Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy","volume":"108","author":"Bohineust","year":"2021","journal-title":"Bull. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/v15071510","article-title":"Virus-specific T-cell therapy for viral infections of the central nervous system: a review","volume":"15","author":"Lambert","year":"2023","journal-title":"Viruses"},{"issue":"5067","key":"10.1016\/j.prp.2024.155518_bib66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib67","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V97.4.994","article-title":"Induction of cytomegalovirus (CMV)\u2013specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions","volume":"97","author":"Peggs","year":"2001","journal-title":"Blood"},{"issue":"8941","key":"10.1016\/j.prp.2024.155518_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib70","doi-asserted-by":"crossref","first-page":"328","DOI":"10.14348\/molcells.2021.0052","article-title":"MHC multimer: a molecular toolbox for immunologists","volume":"44","author":"Chang","year":"2021","journal-title":"Mol. Cells"},{"issue":"17","key":"10.1016\/j.prp.2024.155518_bib71","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.prp.2024.155518_bib72","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.prp.2024.155518_bib73","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-16-2138","article-title":"Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib74","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/icb.2016.71","article-title":"Maintenance of the EBV-specific CD8(+) TCR\u03b1\u03b2 repertoire in immunosuppressed lung transplant recipients","volume":"95","author":"Nguyen","year":"2017","journal-title":"Immunol. Cell Biol."},{"issue":"8","key":"10.1016\/j.prp.2024.155518_bib75","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2022016202","article-title":"Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies","volume":"141","author":"Quach","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006267","article-title":"Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy","volume":"11","author":"Sharma","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.prp.2024.155518_bib77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib78","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4049\/jimmunol.132.1.101","article-title":"Natural suppressor (NS) cells found in the spleen of neonatal mice and adult mice given total lymphoid irradiation (TLI) express the null surface phenotype","volume":"132","author":"Oseroff","year":"1984","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib80","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/77513","article-title":"Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression","volume":"6","author":"Zhang","year":"2000","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib81","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jmcb\/mjr043","article-title":"Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions","volume":"4","author":"Juvet","year":"2012","journal-title":"J. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40364-022-00360-w","article-title":"Application of double-negative T cells in haematological malignancies: recent progress and future directions","volume":"10","author":"Chen","year":"2022","journal-title":"Biomark. Res."},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib83","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.4049\/jimmunol.177.5.2803","article-title":"Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors","volume":"177","author":"Ford","year":"2006","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib84","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2014-03-564286","article-title":"Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency","volume":"124","author":"Rensing-Ehl","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib85","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.4049\/jimmunol.0901533","article-title":"Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype","volume":"183","author":"Crisp\u00edn","year":"2009","journal-title":"J. Immunol."},{"issue":"44","key":"10.1016\/j.prp.2024.155518_bib86","doi-asserted-by":"crossref","first-page":"31880","DOI":"10.1074\/jbc.M113.508655","article-title":"cAMP-responsive element modulator \u03b1 (CREM\u03b1) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease","volume":"288","author":"Hedrich","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"70","key":"10.1016\/j.prp.2024.155518_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib88","article-title":"CD3(+)CD4(-)CD8(-) (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib89","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-18-2291","article-title":"Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-019-0507-2","article-title":"Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15","volume":"7","author":"Yao","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13046-019-1126-y","article-title":"Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade","volume":"38","author":"Fang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib92","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.21873\/anticanres.13795","article-title":"Double-negative T cells inhibit proliferation and invasion of human pancreatic cancer cells in co-culture","volume":"39","author":"Lu","year":"2019","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib93","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","article-title":"Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms","volume":"24","author":"Lee","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155518_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol."},{"issue":"70","key":"10.1016\/j.prp.2024.155518_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci. Immunol."},{"issue":"9","key":"10.1016\/j.prp.2024.155518_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007277","article-title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","volume":"11","author":"Fang","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.prp.2024.155518_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-141505","article-title":"Safety and Efficacy of Ex Vivo Expanded Healthy Donor-Derived Double Negative T Cells for the Treatment of AML Relapsed after Allogeneic Stem Cell Transplantation: A First in-Human Phase I\/IIa Clinical Trial","volume":"136","author":"Baolin","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib98","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.2910160204","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity.","volume":"16","author":"Herberman","year":"1975","journal-title":"Int J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib99","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"Natural\" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2567.2004.01858.x","article-title":"Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Gu\u00e9rin","volume":"112","author":"Esin","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.prp.2024.155518_bib101","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-065X.2006.00451.x","article-title":"Human natural killer cell development","volume":"214","author":"Freud","year":"2006","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib102","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","article-title":"Natural killer cells: a promising immunotherapy for cancer","volume":"20","author":"Chu","year":"2022","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib103","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jcyt.2014.03.009","article-title":"Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease","volume":"16","author":"Davies","year":"2014","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41419-024-06438-7","article-title":"Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"9244","key":"10.1016\/j.prp.2024.155518_bib105","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib106","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","article-title":"Control of Metastasis by NK Cells","volume":"32","author":"L\u00f3pez-Soto","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2024.155518_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112690","article-title":"Antigen-independent killer cells prepared for adoptive immunotherapy: One source, divergent protocols, diverse nomenclature","volume":"477","author":"Torabi-Rahvar","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.prp.2024.155518_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673276","article-title":"CAR-NK cell: a new paradigm in tumor immunotherapy","volume":"11","author":"Marofi","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2024.155518_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00235","article-title":"Natural Regulators\u201d: NK Cells as Modulators of T Cell Immunity","volume":"7","author":"Schuster","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1083462","article-title":"Focusing on NK cells and ADCC: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current Perspectives on \"Off-The-Shelf\" Allogeneic NK and CAR-NK Cell Therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol."},{"issue":"10","key":"10.1016\/j.prp.2024.155518_bib114","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2024.155518_bib115","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front Immunol."},{"issue":"23","key":"10.1016\/j.prp.2024.155518_bib117","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061470","article-title":"iPSC preparation and epigenetic memory: does the tissue origin matter","volume":"10","author":"Scesa","year":"2021","journal-title":"Cells"},{"issue":"7653","key":"10.1016\/j.prp.2024.155518_bib119","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature22312","article-title":"Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations","volume":"545","author":"Merkle","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.prp.2024.155518_bib120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.prp.2024.155518_bib121","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155518_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673276","article-title":"CAR-NK cell: a new paradigm in tumor immunotherapy","volume":"11","author":"Marofi","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib123","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbcan.2018.01.005","article-title":"Reformation in chimeric antigen receptor based cancer immunotherapy: redirecting natural killer cell","volume":"1869","author":"Lin","year":"2018","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.prp.2024.155518_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib127","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2008.048","article-title":"Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes","volume":"20","author":"Jones","year":"2009","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.prp.2024.155518_bib129","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s13287-022-03163-w","article-title":"Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies","volume":"13","author":"Keshavarz","year":"2022","journal-title":"Stem Cell Res. Ther."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib131","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res"},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib132","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.prp.2024.155518_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109446","article-title":"Efficacy of adoptively transferred allogeneic CIK cells on colorectal cancer: augmentative antitumoral effects of GvHD","volume":"114","author":"Muhammadnejad","year":"2023","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib134","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J. Exp. Med"},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/intimm\/dxn042","article-title":"Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers","volume":"20","author":"Sangiolo","year":"2008","journal-title":"Int Immunol."},{"key":"10.1016\/j.prp.2024.155518_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1229540","article-title":"How can Cytokine-induced killer cells overcome CAR-T cell limits","volume":"14","author":"Cappuzzello","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib137","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.exphem.2009.01.010","article-title":"Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes","volume":"37","author":"Franceschetti","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.prp.2024.155518_bib138","article-title":"Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges","volume":"122","author":"Li","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib139","first-page":"298","article-title":"In vitro comparison of cytotoxicity of CD19 CAR-CIK and CD19 CAR-T cells","volume":"20","author":"Moradi","year":"2023","journal-title":"Sci. J. Iran. Blood Transfus. Organ."},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib140","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib141","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.bbmt.2010.05.015","article-title":"Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation","volume":"16","author":"Introna","year":"2010","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"12","key":"10.1016\/j.prp.2024.155518_bib142","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bbmt.2017.07.005","article-title":"Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Introna","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib143","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2011.202","article-title":"The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies","volume":"47","author":"Linn","year":"2012","journal-title":"Bone Marrow Transpl."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib144","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3892\/ol.2014.2558","article-title":"Human leukocyte antigen-haploidentical donor-derived cytokine-induced killer cells are safe and prolong the survival of patients with advanced non-small cell lung cancer","volume":"8","author":"Wang","year":"2014","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib145","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.prp.2024.155518_bib146","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood.V97.10.2923","article-title":"Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production","volume":"97","author":"Baker","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib147","doi-asserted-by":"crossref","DOI":"10.1172\/JCI125986","article-title":"IFN-\u03b3R\/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease","volume":"133","author":"Lu","year":"2023","journal-title":"J. Clin. Invest"},{"issue":"8","key":"10.1016\/j.prp.2024.155518_bib148","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1199311","article-title":"Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies","volume":"5","author":"Cappuzzello","year":"2016","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002475","article-title":"Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells","volume":"9","author":"Dalla Piet\u00e0","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2024.155518_bib150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.molimm.2017.03.017","article-title":"Modification of cytokine-induced killer cells with folate receptor alpha (FR\u03b1)-specific chimeric antigen receptors enhances their antitumor immunity toward FR\u03b1-positive ovarian cancers","volume":"85","author":"Zuo","year":"2017","journal-title":"Mol. Immunol."},{"issue":"12","key":"10.1016\/j.prp.2024.155518_bib151","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \"super-stimulation","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib152","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"28","key":"10.1016\/j.prp.2024.155518_bib153","article-title":"Peripheral monocytosis as a predictive factor for adverse outcome in the emergency department: Survey based on a register study","volume":"96","author":"Hensel","year":"2017","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-7771-2-1","article-title":"Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases","volume":"2","author":"Yang","year":"2014","journal-title":"Biomark. Res"},{"issue":"7","key":"10.1016\/j.prp.2024.155518_bib155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib156","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"13","key":"10.1016\/j.prp.2024.155518_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib158","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2024.155518_bib159","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice","volume":"9","author":"Jayasingam","year":"2019","journal-title":"Front Oncol."},{"issue":"10","key":"10.1016\/j.prp.2024.155518_bib160","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.ymthe.2022.01.046","article-title":"Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment","volume":"30","author":"Xu","year":"2022","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib161","first-page":"166","article-title":"Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity","volume":"67","author":"van Ravenswaay Claasen","year":"1992","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib162","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41598-018-38127-9","article-title":"In-depth characterization of monocyte-derived macrophages using a mass cytometry-based phagocytosis assay","volume":"9","author":"Schulz","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib163","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer","volume":"129","author":"Dong","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2024.155518_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291619","article-title":"Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"issue":"Suppl 3","key":"10.1016\/j.prp.2024.155518_bib165","first-page":"A80","article-title":"132\u2005CAR macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors","volume":"8","author":"Pierini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2024.155518_bib166","doi-asserted-by":"crossref","unstructured":"Pierini S., Gabbasov R., Gabitova L., Ohtani Y., Shestova O., Gill S., et al. Abstract 63: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models2021. 63- p.10.1158\/1538-7445.AM2021-63.","DOI":"10.1158\/1538-7445.AM2021-63"},{"issue":"10","key":"10.1016\/j.prp.2024.155518_bib167","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2024.155518_bib168","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108525","article-title":"Photoresponsive vaccine-like CAR-M system with high-efficiency central immune regulation for inflammation-related depression","volume":"34","author":"Liu","year":"2022","journal-title":"Adv. Mater."},{"issue":"22","key":"10.1016\/j.prp.2024.155518_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223692","article-title":"CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.prp.2024.155518_bib170","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"Suppl 2","key":"10.1016\/j.prp.2024.155518_bib171","first-page":"A334","article-title":"318\u2005Pre-clinical development of a CAR monocyte platform for cancer immunotherapy","volume":"10","author":"Gabitova","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"16_Supplement","key":"10.1016\/j.prp.2024.155518_bib172","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1158\/1538-7445.AM2020-2180","article-title":"Abstract 2180: Genetically engineered chimeric antigen receptor (CAR) monocytes demonstrate targeted anti-tumor activity and differentiate into M1-polarized CAR macrophages","volume":"80","author":"Gabrusiewicz","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2024.155518_bib173","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000002944","article-title":"Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacy","author":"Yang","year":"2024","journal-title":"Chin. Med J. (Engl. )"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib174","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib175","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060994","article-title":"Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy","volume":"11","author":"Paasch","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib176","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/gt.2012.61","article-title":"Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein","volume":"20","author":"Bobadilla","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.prp.2024.155518_bib177","first-page":"7","article-title":"Chimeric antigen receptors that trigger phagocytosis","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.prp.2024.155518_bib178","unstructured":"Therapeutics C. CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors [Available from: \u3008https:\/\/ir.carismatx.com\/news-releases\/news-release-details\/carisma-therapeutics-announces-us-food-and-drug-administration\u3009."},{"issue":"16_suppl","key":"10.1016\/j.prp.2024.155518_bib179","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/JCO.2022.40.16_suppl.2533","article-title":"A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors","volume":"40","author":"Reiss","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155518_bib180","unstructured":"Therapeutics M. Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+ Relapsed\/Refractory PTCL: Myeloid Therapeutics; 2022 [Available from: \u3008https:\/\/myeloidtx.com\/myeloid-therapeutics-announces-fda-fast-track-designation-for-mt-101-for-the-treatment-of-cd5\/\u3009."},{"key":"10.1016\/j.prp.2024.155518_bib181","unstructured":"Therapeutics M. Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1\/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans: Myeloid Therapeutics; 2022 [Available from: \u3008https:\/\/myeloidtx.com\/myeloid-therapeutics-doses-first-patient-with-mt-101-in-the-imagine-phase-1-2-clinical-study\/\u3009."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib182","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","article-title":"The Neutrophil's role during health and disease","volume":"99","author":"Liew","year":"2019","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.prp.2024.155518_bib183","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.yexcr.2016.03.007","article-title":"Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry","volume":"342","author":"Lakschevitz","year":"2016","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.prp.2024.155518_bib184","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fphys.2018.00113","article-title":"Neutrophil: a cell with many roles in inflammation or several cell types","volume":"9","author":"Rosales","year":"2018","journal-title":"Front Physiol."},{"issue":"13","key":"10.1016\/j.prp.2024.155518_bib185","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","article-title":"Neutrophils kill antibody-opsonized cancer cells by trogoptosis","volume":"23","author":"Matlung","year":"2018","journal-title":"Cell Rep."},{"issue":"20","key":"10.1016\/j.prp.2024.155518_bib186","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib187","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2014-03-453217","article-title":"Social networking of human neutrophils within the immune system","volume":"124","author":"Scapini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155518_bib188","article-title":"Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells","volume":"20","author":"Harris","year":"2023","journal-title":"J. Immunol. Regen. Med."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib189","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111128","article-title":"Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy","volume":"40","author":"Chang","year":"2022","journal-title":"Cell Rep."},{"issue":"Suppl 2","key":"10.1016\/j.prp.2024.155518_bib191","first-page":"A375","article-title":"356\u2005Generation of GD2-CAR neutrophils from hPSCs for targeted cancer immunotherapy of solid tumors","volume":"10","author":"Majumder","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib192","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4049\/jimmunol.161.1.375","article-title":"Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains","volume":"161","author":"Roberts","year":"1998","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib193","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13287-019-1165-5","article-title":"Stem cells: past, present, and future","volume":"10","author":"Zakrzewski","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.prp.2024.155518_bib194","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2020.615619","article-title":"Genomic engineering in human hematopoietic stem cells: hype or hope","volume":"2","author":"Klaver-Flores","year":"2021","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.prp.2024.155518_bib195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-4682-10-5","article-title":"Stem cell biology is population biology: differentiation of hematopoietic multipotent progenitors to common lymphoid and myeloid progenitors","volume":"10","author":"Mangel","year":"2013","journal-title":"Theor. Biol. Med Model"},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib196","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.prp.2024.155518_bib197","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1089\/hum.2012.202","article-title":"Modification of hematopoietic stem\/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy","volume":"24","author":"De Oliveira","year":"2013","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"10.1016\/j.prp.2024.155518_bib198","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mt.2015.102","article-title":"HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells","volume":"23","author":"Zhen","year":"2015","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.prp.2024.155518_bib199","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib200","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","article-title":"New cell sources for T cell engineering and adoptive immunotherapy","volume":"16","author":"Themeli","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.prp.2024.155518_bib201","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib202","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00005-021-00640-7","article-title":"Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies","volume":"70","author":"Mazza","year":"2021","journal-title":"Arch. Immunol. Ther. Exp"},{"issue":"9","key":"10.1016\/j.prp.2024.155518_bib203","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092266","article-title":"Engineering induced pluripotent stem cells for cancer immunotherapy","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib204","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","article-title":"3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells.","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.prp.2024.155518_bib205","series-title":"Molecular Players in iPSC Technology","first-page":"95","article-title":"Chapter 3 - Improving the safety of iPSC-derived T cell therapy","author":"Ando","year":"2022"},{"issue":"Supplement 1","key":"10.1016\/j.prp.2024.155518_bib206","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2022-167194","article-title":"Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed\/Refractory B-Cell Malignancies","volume":"140","author":"Mehta","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.prp.2024.155518_bib207","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155518_bib208","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2023-182313","article-title":"Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: a case study","volume":"142","author":"Ramachandran","year":"2023","journal-title":"Blood"},{"issue":"6478","key":"10.1016\/j.prp.2024.155518_bib209","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.prp.2024.155518_bib210","article-title":"T cell-derived exosomes in tumor immune modulation and immunotherapy","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.prp.2024.155518_bib211","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126234","article-title":"Tumor-Derived Exosomes (TEX) and Their Role in Immuno-Oncology","volume":"22","author":"Whiteside","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155518_bib212","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5879616","article-title":"Circulating cancer stem cell-derived extracellular vesicles as a novel biomarker for clinical outcome evaluation","volume":"2019","author":"Brocco","year":"2019","journal-title":"J. Oncol."},{"issue":"19","key":"10.1016\/j.prp.2024.155518_bib213","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194748","article-title":"High blood concentration of leukocyte-derived extracellular vesicles is predictive of favorable clinical outcomes in patients with pancreatic cancer: results from a multicenter prospective study","volume":"14","author":"Brocco","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155518_bib214","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771551","article-title":"Immune cell-derived extracellular vesicles - new strategies in cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5483\/BMBRep.2022.55.1.133","article-title":"Immune cell-derived small extracellular vesicles in cancer treatment","volume":"55","author":"Choi","year":"2022","journal-title":"BMB Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib216","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.prp.2024.155518_bib217","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050790","article-title":"T Lymphocyte and CAR-T Cell-Derived Extracellular Vesicles and Their Applications in Cancer Therapy","volume":"11","author":"Calvo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prp.2024.155518_bib218","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2020.07.033","article-title":"Tropism-facilitated delivery of CRISPR\/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies","volume":"326","author":"Xu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2024.155518_bib219","article-title":"Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung","volume":"1","author":"Popowski","year":"2022","journal-title":"Extra Vesicle"},{"issue":"9","key":"10.1016\/j.prp.2024.155518_bib220","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","article-title":"Inhalable dry powder mRNA vaccines based on extracellular vesicles","volume":"5","author":"Popowski","year":"2022","journal-title":"Matter"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib221","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12967-023-04206-3","article-title":"Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer","volume":"21","author":"Zheng","year":"2023","journal-title":"J. Transl. Med."},{"issue":"17","key":"10.1016\/j.prp.2024.155518_bib222","doi-asserted-by":"crossref","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","article-title":"Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy","volume":"17","author":"Zhu","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib223","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/acs.nanolett.8b03439","article-title":"Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles","volume":"19","author":"Li","year":"2019","journal-title":"Nano Lett."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib224","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1021\/acsnano.9b01004","article-title":"Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders","volume":"13","author":"Riazifar","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12967-023-04206-3","article-title":"Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer","volume":"21","author":"Zheng","year":"2023","journal-title":"J. Transl. Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib226","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12964-022-00959-4","article-title":"A review on exosomes application in clinical trials: perspective, questions, and challenges","volume":"20","author":"Rezaie","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.prp.2024.155518_bib227","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.prp.2024.155518_bib228","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061401","article-title":"CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity","volume":"13","author":"Haque","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2024.155518_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104262","article-title":"The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth","volume":"360","author":"Yang","year":"2021","journal-title":"Cell. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2024.155518_bib230","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040919","article-title":"Artificial extracellular vesicles generated from t cells using different induction techniques","volume":"12","author":"Zmievskaya","year":"2024","journal-title":"Biomedicines"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824004291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824004291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:30:54Z","timestamp":1727184654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824004291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":230,"alternative-id":["S0344033824004291"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155518","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential alternatives to \u03b1\u03b2-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155518"}}